Innovations in linker design are focused on multiple issues ranging from serum stability to mechanism of release to drug to antibody ratio (DAR). As linkers become increasingly …

Dec 1, 2021 · Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The antibody–drug conjugate linker molecule determines both the efficacy and the …

Jul 1, 2025 · Antibody-drug conjugates (ADCs) 1, 2 are innovative therapeutic agents that combine monoclonal antibodies with cytotoxic drugs via chemical linkers 3, enabling precise …

May 27, 2025 · Linker tethering payload to antibody is vital for ADC. This review provides an overview of linkers of 17 approved ADCs and recent innovations in linker design, focusing on …

Sep 30, 2024 · Antibody-drug conjugates (ADCs) are “biological bullets” that combine cytotoxic drugs (payloads) with antibodies through “linkers.” ADCs consist of five key elements: target, …

An antibody is linked to a small molecule via a covalent tether. A linker may be a small part of an antibody-drug conjugate, but drugmakers are finding that linker chemistry is important.

Jun 23, 2021 · The development of antibody-drug conjugates (ADCs) has significantly been advanced in the past decade given the improvement of payloads, linkers and conjugation …

Aug 2, 2025 · Inspired by the "magic bullet" concept proposed over a century ago, antibody-drug conjugates (ADCs) are developed to enhance cancer therapy by linking monoclonal antibodies …

2 days ago · The promise of antibody-drug conjugates lies not just in their novel mechanism but in the precision of their design. Every decision, from antibody specificity and linker chemistry to …

NJ Bio, Inc., offers the following payload-linker services: Payload Synthesis and Optimization Synthesis of linkers with compatible conjugation chemistry and suitable release mechanisms …